oid_409e700c-9a26-ec11-b6e56045bd8c111a_Concr_logo_CMYK.png

Concr

Other

  • Funding stage: Seed
  • Technology type: Tech Bio
Membership category
Emerging Y1

11 Milbrook, 11 Milbrook, Esher, KT10 9EJ, United Kingdom

Concr at a glance

Enabling precision oncology by predicting therapeutic response for every individual

About Concr

Concr is a techbio company providing predictive modelling solutions to enhance confidence and foresight about therapeutic efficacy of existing and emerging cancer drugs. By accurately predicting response for individual patients and cohorts, we enable more efficacious and informative trials, thereby improving probability of success of novel cancer therapeutics. 

Our Farr-Sight® platform, built on decades of astrophysics research, models diverse data interactions to simulate human disease biology, enabling accurate predictions with minimal data. This is especially valuable in early-stage drug development and rare cancers.

Validated through collaborations with Roche, Step Pharma, The Institute of Cancer Research, The Christie NHS Foundation Trust, Durham University, and The University of Queensland, our solutions are trusted by researchers in industry, academia and healthcare. 

Therapeutic area(s)

Articles Concr has contributed to